What is CagriSema?

CagriSema is a fixed mix of two drugs in one weekly shot: cagrilintide, a long-acting drug that switches on the amylin receptor, plus semaglutide, a GLP-1 drug. It is not cagrilintide alone and not semaglutide alone. The largest study of CagriSema, REDEFINE 2, in 1,206 people with type 2 diabetes, found 13.7% weight loss versus 3.4% at 68 weeks. A smaller study in 92 adults with type 2 diabetes found 15.6% at 32 weeks, versus 5.1% on semaglutide alone and 8.1% on cagrilintide alone. On its own, cagrilintide gave 6.0% to 10.8% weight loss at 26 weeks in 706 people, versus 3.0% on a dummy shot. On its own, semaglutide as Wegovy 2.4 milligrams gave 14.9% at 68 weeks in STEP 1. CagriSema is still experimental. Full record at /compounds/cagrilintide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.